English | Español

Glaxosmithkline
+ Technology/Innovation
Bree Gonzales | Feb 2, 2022

Molnupiravir is now the last choice for COVID-19: 'The Merck product is only 30% effective'
+ Technology/Innovation
Carol Ostrow | Dec 16, 2017

Multiple myeloma study results encouraging, GSK says
+ Regulatory
Carol Ostrow | Dec 15, 2017

GSK receives FDA approval for expanded use of Nucala
+ Technology/Innovation
Carol Ostrow | Dec 15, 2017

GSK says Shingrix promising for preventing shingles in stem cell transplant patients
+ Regulatory
Carol Ostrow | Sep 24, 2017

GlaxoSmithKline, Innoviva COPD therapy gains FDA approval
+ Regulatory
Carol Ostrow | Sep 23, 2017

Self-injectable form of Lupus therapy clears hurdle in Europe
+ Regulatory
Carol Ostrow | Sep 21, 2017

GSK’s Shingrix shingles vaccine clears an FDA hurdle
+ Technology/Innovation
Carol Ostrow | Sep 18, 2017

Salford Lung Study shows promise for GlaxoSmithKline asthma treatment

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation